VISP
This article was originally published in The Tan Sheet
Executive Summary
More than 2,600 subjects enrolled in NIH-sponsored Vitamin Intervention for Stroke Prevention Study, with recruitment expected to continue through 2001, to reach 3,600-patient target, according to an abstract presented at the 26th International Stroke Conference in Fort Lauderdale, Fla. Feb. 14-16. VISP is a double-blind, randomized, controlled trial with centers in U.S., Canada and Scotland; subjects receive either low or high doses of folic acid, vitamins B6 and B12. Primary outcome is recurrent cerebral infarction. Separately, enrollment will continue until 2003 for 8,000-patient VITATOPS study examining whether B vitamins reduce combined incidence of recurrent vascular events and vascular death in patients with recent stroke or TIA. Study encompasses centers in Australia, New Zealand, Italy, U.K